- Home
- CMAX vs OGEN Comparison
CMAX vs OGEN Comparison
Compare CMAX & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMAX
- OGEN
- Stock Information
- Founded
- CMAX 2011
- OGEN 1996
- Country
- CMAX United States
- OGEN United States
- Employees
- CMAX N/A
- OGEN N/A
- Industry
- CMAX Computer Software: Prepackaged Software
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CMAX Technology
- OGEN Health Care
- Exchange
- CMAX Nasdaq
- OGEN Nasdaq
- Market Cap
- CMAX 7.6M
- OGEN 4.5M
- IPO Year
- CMAX N/A
- OGEN N/A
- Fundamental
- Price
- CMAX $1.85
- OGEN $0.34
- Analyst Decision
- CMAX Hold
- OGEN
- Analyst Count
- CMAX 2
- OGEN 0
- Target Price
- CMAX $33.20
- OGEN N/A
- AVG Volume (30 Days)
- CMAX 58.0K
- OGEN 392.1K
- Earning Date
- CMAX 11-07-2024
- OGEN 11-07-2024
- Dividend Yield
- CMAX N/A
- OGEN N/A
- EPS Growth
- CMAX N/A
- OGEN N/A
- EPS
- CMAX N/A
- OGEN N/A
- Revenue
- CMAX $784,551,000.00
- OGEN $7,466.00
- Revenue This Year
- CMAX $13.01
- OGEN N/A
- Revenue Next Year
- CMAX $32.42
- OGEN N/A
- P/E Ratio
- CMAX N/A
- OGEN N/A
- Revenue Growth
- CMAX 9.06
- OGEN N/A
- 52 Week Low
- CMAX $1.55
- OGEN $0.29
- 52 Week High
- CMAX $74.70
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- CMAX 46.01
- OGEN 36.96
- Support Level
- CMAX $1.60
- OGEN $0.29
- Resistance Level
- CMAX $2.39
- OGEN $0.35
- Average True Range (ATR)
- CMAX 0.19
- OGEN 0.04
- MACD
- CMAX 0.07
- OGEN 0.02
- Stochastic Oscillator
- CMAX 32.50
- OGEN 31.19
About CMAX CareMax Inc.
CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.